BioCentury
ARTICLE | Clinical News

Deflazacort: Phase III data

April 25, 2016 7:00 AM UTC

A double-blind, international Phase III trial in 196 DMD patients showed that once-daily 0.9 and 1.2 mg/kg deflazacort each met the primary endpoint of improving muscle strength from baseline to week ...